Literature DB >> 25204669

Environmental risk factors for inflammatory bowel diseases: a review.

Ashwin N Ananthakrishnan1.   

Abstract

Inflammatory bowel diseases comprising Crohn's disease (CD) and ulcerative colitis (UC) are chronic immunologically mediated diseases. The key mechanism underlying the pathogenesis of these diseases is a dysregulated immune response to commensal flora in a genetically susceptible host. Thus intestinal microbial dysbiosis, host genetics, and the external environment all play an important role in the development of incident disease and in determining subsequent disease behavior and outcomes. There are several well-defined or putative environmental risk factors including cigarette smoking, appendectomy, diet, stress and depression, vitamin D as well as hormonal influence. The effect of some of the risk factors appears to differ between CD and UC suggesting that despite shared genetic and immunologic mechanisms, distinct pathways of pathogenesis exist. There is a growing body of literature identifying risk factors for incident disease. There is less rigorous literature defining triggers of relapse, and few controlled clinical trials examining if modification of such risk factors results in an improvement in patient outcomes. This is an area of considerable patient, physician, and scientific interest, and there is an important unmet need for rigorous studies of the external environment in disease pathogenesis and subsequent course.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25204669      PMCID: PMC4304948          DOI: 10.1007/s10620-014-3350-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  110 in total

1.  Dietary beliefs and behavior among inflammatory bowel disease patients.

Authors:  Camille Zallot; Didier Quilliot; Jean-Baptiste Chevaux; Carina Peyrin-Biroulet; Rosa Maria Guéant-Rodriguez; Estelle Freling; Benjamin Collet-Fenetrier; Nicolas Williet; Olivier Ziegler; Marc-André Bigard; Jean-Louis Guéant; Laurent Peyrin-Biroulet
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

2.  Geographical variation and incidence of inflammatory bowel disease among US women.

Authors:  Hamed Khalili; Edward S Huang; Ashwin N Ananthakrishnan; Leslie Higuchi; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Gut       Date:  2012-01-11       Impact factor: 23.059

3.  Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors.

Authors:  J R Goodhand; M Wahed; J E Mawdsley; A D Farmer; Q Aziz; D S Rampton
Journal:  Inflamm Bowel Dis       Date:  2012-02-22       Impact factor: 5.325

4.  Hormone therapy increases risk of ulcerative colitis but not Crohn's disease.

Authors:  Hamed Khalili; Leslie M Higuchi; Ashwin N Ananthakrishnan; JoAnn E Manson; Diane Feskanich; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Gastroenterology       Date:  2012-07-27       Impact factor: 22.682

5.  Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

Authors:  A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

6.  Antibiotic exposure and IBD development among children: a population-based cohort study.

Authors:  Matthew P Kronman; Theoklis E Zaoutis; Kevin Haynes; Rui Feng; Susan E Coffin
Journal:  Pediatrics       Date:  2012-09-24       Impact factor: 7.124

7.  Association between depressive symptoms and incidence of Crohn's disease and ulcerative colitis: results from the Nurses' Health Study.

Authors:  Ashwin N Ananthakrishnan; Hamed Khalili; An Pan; Leslie M Higuchi; Punyanganie de Silva; James M Richter; Charles S Fuchs; Andrew T Chan
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-31       Impact factor: 11.382

8.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment.

Authors:  Xochitl C Morgan; Timothy L Tickle; Harry Sokol; Dirk Gevers; Kathryn L Devaney; Doyle V Ward; Joshua A Reyes; Samir A Shah; Neal LeLeiko; Scott B Snapper; Athos Bousvaros; Joshua Korzenik; Bruce E Sands; Ramnik J Xavier; Curtis Huttenhower
Journal:  Genome Biol       Date:  2012-04-16       Impact factor: 13.583

9.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.

Authors:  Luke Jostins; Stephan Ripke; Rinse K Weersma; Richard H Duerr; Dermot P McGovern; Ken Y Hui; James C Lee; L Philip Schumm; Yashoda Sharma; Carl A Anderson; Jonah Essers; Mitja Mitrovic; Kaida Ning; Isabelle Cleynen; Emilie Theatre; Sarah L Spain; Soumya Raychaudhuri; Philippe Goyette; Zhi Wei; Clara Abraham; Jean-Paul Achkar; Tariq Ahmad; Leila Amininejad; Ashwin N Ananthakrishnan; Vibeke Andersen; Jane M Andrews; Leonard Baidoo; Tobias Balschun; Peter A Bampton; Alain Bitton; Gabrielle Boucher; Stephan Brand; Carsten Büning; Ariella Cohain; Sven Cichon; Mauro D'Amato; Dirk De Jong; Kathy L Devaney; Marla Dubinsky; Cathryn Edwards; David Ellinghaus; Lynnette R Ferguson; Denis Franchimont; Karin Fransen; Richard Gearry; Michel Georges; Christian Gieger; Jürgen Glas; Talin Haritunians; Ailsa Hart; Chris Hawkey; Matija Hedl; Xinli Hu; Tom H Karlsen; Limas Kupcinskas; Subra Kugathasan; Anna Latiano; Debby Laukens; Ian C Lawrance; Charlie W Lees; Edouard Louis; Gillian Mahy; John Mansfield; Angharad R Morgan; Craig Mowat; William Newman; Orazio Palmieri; Cyriel Y Ponsioen; Uros Potocnik; Natalie J Prescott; Miguel Regueiro; Jerome I Rotter; Richard K Russell; Jeremy D Sanderson; Miquel Sans; Jack Satsangi; Stefan Schreiber; Lisa A Simms; Jurgita Sventoraityte; Stephan R Targan; Kent D Taylor; Mark Tremelling; Hein W Verspaget; Martine De Vos; Cisca Wijmenga; David C Wilson; Juliane Winkelmann; Ramnik J Xavier; Sebastian Zeissig; Bin Zhang; Clarence K Zhang; Hongyu Zhao; Mark S Silverberg; Vito Annese; Hakon Hakonarson; Steven R Brant; Graham Radford-Smith; Christopher G Mathew; John D Rioux; Eric E Schadt; Mark J Daly; Andre Franke; Miles Parkes; Severine Vermeire; Jeffrey C Barrett; Judy H Cho
Journal:  Nature       Date:  2012-11-01       Impact factor: 49.962

10.  An altered gut microbiome profile in a child affected by Crohn's disease normalized after nutritional therapy.

Authors:  Valeria D'Argenio; Vincenza Precone; Giorgio Casaburi; Erasmo Miele; Massimo Martinelli; Annamaria Staiano; Francesco Salvatore; Lucia Sacchetti
Journal:  Am J Gastroenterol       Date:  2013-05       Impact factor: 10.864

View more
  44 in total

Review 1.  The global burden of IBD: from 2015 to 2025.

Authors:  Gilaad G Kaplan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-01       Impact factor: 46.802

2.  The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases.

Authors:  G Conway; G Velonias; E Andrews; J J Garber; V Yajnik; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2017-01-20       Impact factor: 8.171

3.  Vitamin D Deficiency Associated with Disease Activity in Patients with Inflammatory Bowel Diseases.

Authors:  Mehdi Torki; Ali Gholamrezaei; Leila Mirbagher; Manijeh Danesh; Sara Kheiri; Mohammad Hassan Emami
Journal:  Dig Dis Sci       Date:  2015-06-02       Impact factor: 3.199

Review 4.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

5.  Interaction between smoking and ATG16L1T300A triggers Paneth cell defects in Crohn's disease.

Authors:  Ta-Chiang Liu; Justin T Kern; Kelli L VanDussen; Shanshan Xiong; Gerard E Kaiko; Craig B Wilen; Michael W Rajala; Roberta Caruso; Michael J Holtzman; Feng Gao; Dermot Pb McGovern; Gabriel Nunez; Richard D Head; Thaddeus S Stappenbeck
Journal:  J Clin Invest       Date:  2018-10-15       Impact factor: 14.808

Review 6.  Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.

Authors:  Taekil Eom; Yong Sung Kim; Chang Hwan Choi; Michael J Sadowsky; Tatsuya Unno
Journal:  J Microbiol       Date:  2018-02-28       Impact factor: 3.422

7.  Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice.

Authors:  Kazuhiko Ono; Satoshi Nimura; Yuko Hideshima; Kazuki Nabeshima; Manabu Nakashima
Journal:  Exp Ther Med       Date:  2017-10-03       Impact factor: 2.447

8.  High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease.

Authors:  Robin G Wilson; Betsy W Stevens; Abra Y Guo; Caitlin N Russell; Anna Thornton; Melissa A Cohen; Holly C Sturgeon; Cosmas Giallourakis; Hamed Khalili; Deanna D Nguyen; Vijay Yajnik; Jenny Sauk; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2015-02-21       Impact factor: 3.199

Review 9.  Ulcerative Colitis: Update on Medical Management.

Authors:  Heba N Iskandar; Tanvi Dhere; Francis A Farraye
Journal:  Curr Gastroenterol Rep       Date:  2015-11

Review 10.  The effect of NOD2 on the microbiota in Crohn's disease.

Authors:  Mackenzie L Lauro; Jason M Burch; Catherine Leimkuhler Grimes
Journal:  Curr Opin Biotechnol       Date:  2016-03-29       Impact factor: 9.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.